Oh, they’re trying to get rofecoxib back on the market in the US as an orphan drug for hemophilic arthropathy, despite celecoxib already existing and Vioxx having been pulled from the market after Bayer got caught hiding the obscene CV risk profile from the public. Once it’s available for people with joint damage from hemophilia there’s nothing (except a REMS program robust enough to keep it from coming back to market which, lol lmao) to stop it from being prescribed to anyone for anything.
All of the NSAIDs have some combination of GI, CV, and nephrotoxicity risks. Celecoxib is the least worst of them, but it still exists in the shadow of Vioxx. The conventional NSAIDs (except for naproxen and aspirin) are all associated with varying degrees of GI or CV risk and nephrotoxicity. It’s a class effect, some are worse than others, celecoxib and naproxen seem to have the best risk/benefit ratio for people who can take NSAIDs.
Oh, they’re trying to get rofecoxib back on the market in the US as an orphan drug for hemophilic arthropathy, despite celecoxib already existing and Vioxx having been pulled from the market after Bayer got caught hiding the obscene CV risk profile from the public. Once it’s available for people with joint damage from hemophilia there’s nothing (except a REMS program robust enough to keep it from coming back to market which, lol lmao) to stop it from being prescribed to anyone for anything.
All of the NSAIDs have some combination of GI, CV, and nephrotoxicity risks. Celecoxib is the least worst of them, but it still exists in the shadow of Vioxx. The conventional NSAIDs (except for naproxen and aspirin) are all associated with varying degrees of GI or CV risk and nephrotoxicity. It’s a class effect, some are worse than others, celecoxib and naproxen seem to have the best risk/benefit ratio for people who can take NSAIDs.
Great info! I’m shocked to hear they’re trying to get rofecoxib back on the market. Fuckin’ Merck.